Arbeitsrecht und Vergütung für Führungskräfte

Kapitalmarkt

Gesellschaftsrecht / M&A

IP / IT

Steuern

Vectivio

On April 9, 2021, VectivBio Holding AG announced its initial public offering and listing of its shares on Nasdaq (ticker symbol VECT). VectivBio is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Through its IPO, at USD 17 per share, VectivBio raises gross proceeds of USD 146.6 m (including greenshoe). At market close on the first day of trading, VectivBio had a market capitalization of USD 824 m.
Homburger advises VectivBio Holding AG in this matter. The Homburger team includes partner Andreas Müller (Capital Markets; Corporate / M&amp;A; Employment and Executive Compensation), lead associate Margrit Marti, associates Angela Oppliger and Kevin Hubacher and junior associate Daniel Bötticher (all Capital Markets; Corporate / M&amp;A), partner Stefan Oesterhelt and associates Joël Gyger and Raphaël Fellay (all Tax), and partner Luca Dal Molin (IP/IT).

Homburger advises VectivBio on its IPO on Nasdaq

On October 15, 2020, VectivBio AG, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, announced that it has closed a USD 110 m crossover financing from new investors Surveyor Capital (a Citadel company), Cormorant Capital and Eventide Asset Management, with participation from existing investors Versant Ventures, OrbiMed, Novo Holdings, BPI France, Tekla Healthcare Investors, Inserm Transfert Initiative and Cowen Healthcare Investments.
Proceeds from the financing will be used to support the further clinical development of VectivBio&#8217;s lead investigational product, apraglutide, to treat short bowel syndrome (SBS), early commercialization activities and further development of the pipeline through business development initiatives.
The Homburger team was led by partner Andreas Müller and included lead associate Margrit Marti, associates Angela Oppliger and Mirko Stiefel and transaction and corporate support specialist Carolina Rodriguez (all Corporate / M&amp;A), partner Luca Dal Molin and associate Kirsten Schmidt (both IP / IT) as well as partner Stefan Oesterhelt and associates Joël Gyger and Raphaël Fellay (all Tax).

Homburger advises VectivBio on USD 110 m Crossover Financing

Immobilien

Novartis

September 3, 2020. A subsidiary of Novartis AG (SIX: NOVN) has sold a production facility located at the Schweizerhalle industrial park to Syngenta Crop Protection AG.
Homburger advised Novartis in this matter. The Homburger team was led by Daniel Häusermann (Corporate / M&amp;A) and included Luca Dal Molin (IP / IT), Stefan Gäumann (Real Estate), Aron Waltuch (Corporate / M&amp;A), Marc Bircher (Employment and Executive Compensation) and Joël Gyger (Tax) as well as junior associate Oriana Schöni (Corporate / M&amp;A). Marcel Dietrich (Real Estate) acted as senior relationship partner.

Joël
Gyger

Homburger advises VectivBio on its IPO on Nasdaq

Homburger advises VectivBio on USD 110 m Crossover Financing

Homburger advised Novartis on its sale of a production facility to Syngenta

Join the Team

Joël Gyger

Karriere

Sprachen

Zulassung

Teams

JoëlGyger

Homburger advises VectivBio on its IPO on Nasdaq

Homburger advises VectivBio on USD 110 m Crossover Financing

Homburger advised Novartis on its sale of a production facility to Syngenta

Join the Team

Joël Gyger

Karriere

Sprachen

Zulassung

Teams

Joël
Gyger